Patents Assigned to MedImmune Limited
  • Targeted binding agents against B7-H1
    Patent number: 8779108
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: July 15, 2014
    Assignee: MedImmune, Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
  • Nucleic acid molecule encoding a specific IL-1R1 antibody
    Patent number: 8741604
    Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 3, 2014
    Assignee: Medimmune Limited
    Inventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
  • Binding Members For IgE Molecules
    Publication number: 20140127212
    Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
    Type: Application
    Filed: November 16, 2012
    Publication date: May 8, 2014
    Applicant: MedImmune Limited
    Inventor: MedImmune Limited
  • Methods of obtaining a specific binding member that binds eotaxin
    Patent number: 8715961
    Abstract: Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: May 6, 2014
    Assignee: Medimmune Limited
    Inventors: Tristan John Vaughan, Alison Jane Wilton, Stephen Smith, Sarah Helen Main
  • Compositions and methods for producing gamma-carboxylated proteins
    Patent number: 8697440
    Abstract: The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and ?-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated protein.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: April 15, 2014
    Assignee: Medimmune Limited
    Inventors: Christel Fenge, Ann Lövgren, Anders Thelin
  • Targeted binding agents directed to PDGRF-alpha and uses thereof
    Patent number: 8697664
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 15, 2014
    Assignee: MedImmune Limited
    Inventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, Sue A. Cartlidge, David Charles Blakey
  • RSV SPECIFIC BINDING MOLECULE
    Publication number: 20140093500
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 3, 2014
    Applicant: MEDIMMUNE LIMITED
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20140072575
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 13, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER
    Publication number: 20140023654
    Abstract: The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.
    Type: Application
    Filed: July 29, 2013
    Publication date: January 23, 2014
    Applicant: Medimmune Limited
    Inventors: Jeffrey Lester BROWN, Stephen Charles Emery, David Charles Blakey
  • Chinese Hamster Ovary Cell Line
    Publication number: 20140011237
    Abstract: The present invention is related to a Chinese hamster ovary cell line as deposited with the European Collection of Cell Cultures (ECACC) under accession number 10090201; use of the cell line for the production of a recombinant polypeptide; a kit comprising the cell line; and methods for the production of recombinant polypeptide.
    Type: Application
    Filed: September 14, 2011
    Publication date: January 9, 2014
    Applicant: MedImmune Limited
    Inventors: Diane Hatton, Ray Field, Wyn Forrest-Owen, Victoria Richardson
  • ANTI-IL-18 ANTIBODIES AND THEIR USES
    Publication number: 20140004128
    Abstract: The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.
    Type: Application
    Filed: December 20, 2011
    Publication date: January 2, 2014
    Applicant: Medimmune Limited
    Inventors: Claire Dobson, Steven Lane, Philip Newton, Martin Schwickart, Ann-Charlott Steffen
  • NEUTRALIZING ANTIBODIES AGAINST GDF-8 AND USES THEREFOR
    Publication number: 20130287762
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 31, 2013
    Applicants: MEDIMMUNE LIMITED, WYETH
    Inventors: Geetruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove, Anne Field, Caroline Russell, Viia Valge-Archer
  • RSV specific binding molecule
    Patent number: 8568726
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: October 29, 2013
    Assignee: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Bakker, Etsuko Yasuda
  • FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS
    Publication number: 20130280236
    Abstract: The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).
    Type: Application
    Filed: September 19, 2011
    Publication date: October 24, 2013
    Applicant: MEDIMMUNE LIMITED
    Inventors: Ann Eva Monica Lõvgren, Kenny M. Hansson
  • THERAPIES FOR IMPROVING PULMONARY FUNCTION
    Publication number: 20130281876
    Abstract: The disclosure relates to IL-13 antagonists, in particular anti-human-IL-13 antibodies and human-IL-13-binding fragments thereof, and their use for improvement, maintenance or reduction in the rate of decline of pulmonary function in a subject with impaired pulmonary function, which may be associated with uncontrolled moderate-to-asthma, COPD or IPF.
    Type: Application
    Filed: October 14, 2011
    Publication date: October 24, 2013
    Applicant: MEDIMMUNE LIMITED
    Inventors: Raffaella Faggioni, Richard May, Chris Kell, Nester Molfino, Lorin Roskos
  • Stabilized Angiopoietin-2 Antibodies And Uses Thereof
    Publication number: 20130280251
    Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
    Type: Application
    Filed: July 1, 2013
    Publication date: October 24, 2013
    Applicant: MedImmune Limited
    Inventors: Vahe Bedian, William Dall'Acqua, Herren Wu, Michael Bowen, Jeffrey Brown, Chris Stannard, Ralph Minter, Andrew Buchanan
  • RSV-specific binding molecules and means for producing them
    Patent number: 8562996
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: October 22, 2013
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont
  • Method of mutagenesis
    Patent number: 8518645
    Abstract: The present invention relates to a method of mutagenesis for introducing mutations into a molecule and, in particular, to methods that may be applied to populations of molecules for the generation or screening of libraries involving the mutation of multiple molecules.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: August 27, 2013
    Assignee: MedImmune Limited
    Inventors: Ralph Raymond Minter, Steven Godfrey Lane, Robert George Edward Holgate, Maria Anastasia Theresa Groves
  • Antibody molecule for human GM-CSF receptor alpha
    Patent number: 8506960
    Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: August 13, 2013
    Assignees: MedImmune Limited, Zenyth Operations Pty. Ltd.
    Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
  • Stabilized angiopoietin-2 antibodies and uses thereof
    Patent number: 8507656
    Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: August 13, 2013
    Assignee: MedImmune Limited
    Inventors: Vahe Bedian, William Dall'Acqua, Herren Wu, Michael Bowen, Jeffrey Brown, Chris Stannard, Ralph Minter, Andrew Buchanan